Search results
Antoni Ribas, M.D., Ph.D., conducts laboratory and clinical research focused on malignant melanoma, an aggressive form of skin cancer for which few effective therapies exist. He seeks to develop immunotherapy and targeted stem cell-based approaches that harness a patient’s own immune system to combat melanoma and other cancers.
Antoni Ribas is a Spanish American physician–scientist. He is a Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA) and Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center.
Antoni Ribas, MD, PhD, is professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA), director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA.
- (58)
- (310) 794-4955
- 100 Medical Plaza, Los Angeles, 90095
Pembrolizumab versus ipilimumab in advanced melanoma. C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532. , 2015. 6221....
Antoni Ribas, M.D., Ph.D., is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered T-cells, PD-1 blockade therapy and BRAF targeted therapies.
Antoni Ribas, MD, PhD. Professor of Medicine, Surgery, and Molecular and Medical Pharmacology; Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center
Dec 11, 2019 · Cel Cell Biology Mol Molecular Biology. Translation: Humans Cells. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat Commun. 2024 Feb 09; 15 (1):1244.
